KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Gains from Sales and Divestitures (2016 - 2025)

Historic Gains from Sales and Divestitures for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q4 2025 value amounting to $736238.0.

  • CRISPR Therapeutics AG's Gains from Sales and Divestitures rose 6335.4% to $736238.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $736238.0, marking a year-over-year increase of 6335.4%. This contributed to the annual value of $736238.0 for FY2025, which is 6335.4% up from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Gains from Sales and Divestitures of $736238.0 as of Q4 2025, which was up 6335.4% from $590587.0 recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Gains from Sales and Divestitures registered a high of $736238.0 during Q4 2025, and its lowest value of $109355.0 during Q1 2021.
  • Over the past 5 years, CRISPR Therapeutics AG's median Gains from Sales and Divestitures value was $272278.5 (recorded in 2023), while the average stood at $309757.3.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Gains from Sales and Divestitures skyrocketed by 208710.0% in 2021 and then plummeted by 4775.78% in 2022.
  • Over the past 5 years, CRISPR Therapeutics AG's Gains from Sales and Divestitures (Quarter) stood at $455440.0 in 2021, then plummeted by 47.76% to $237932.0 in 2022, then increased by 16.76% to $277808.0 in 2023, then soared by 62.23% to $450701.0 in 2024, then skyrocketed by 63.35% to $736238.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $736238.0 for Q4 2025, versus $590587.0 for Q3 2025 and $501884.0 for Q2 2025.